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This daily COVID-19 Health Evidence Summary is to signpost DFID and other UK government 
departments to the latest relevant evidence and discourse on COVID-19 to inform and support 
their response. It is a result of 3 hours of work and is not intended to be a comprehensive summary 
of available evidence on COVID-19 but aims to make original documents easily accessible to 

















The Lancet HIV 
| Article 
 This observational prospective 
study characterises individuals 
aged >=18y with COVID-19 
among a cohort of HIV-infected 
adults in Madrid. Included as 
information about incidence, 
clinical characteristics and 
outcomes of HIV-infected 
individuals with SARS-CoV-2 
infection is scarce 
 As of 30 April 2020, 51 COVID-19 
cases were diagnosed among a 
cohort of 2873 HIV-infected 
individuals 
 COVID-19 presented similar 
clinical, laboratory and radiological 
features in HIV-infected individuals 
compared with reports of the 
general population 
 Among HIV-infected individuals, 
lower CD4 cell counts affected 
disease severity and viral kinetics 
suggesting that those with low 
CD4 cell counts might have worse 
2 
outcomes than individuals with 
restored immunity 
 HIV-infected individuals should 
receive the same treatment 











The Lancet | 
Article 
 This prospective observational 
study in the UK describes the 
clinical and demographic 
characterises and C19 outcomes 
in patients with cancer. Included 
as data from large multicentre 
studies to support the assumption 
that individuals with cancer are at 
increased risk of mortality from 
C19 are scarce 
 Authors did not identify evidence 
that cancer patients on cytotoxic 
chemotherapy or other anti-cancer 
treatments are at increased risk of 
mortality from C19, compared to 
those not on active treatment 
 Mortality from COVID-19 in cancer 
patients appears to be driven by 
age, sex and co-morbidities 




a cohort study 
The Lancet | 
Article 
 This study characterises outcomes 
of a cohort of 928 patients aged 
>=18y with cancer and COVID-19 
from the USA, Canada and Spain 
from the COVID-19 and Cancer 
Consortium (CCC19) database 
diverse in terms of age 
distribution, race and ethnicity, 
cancer status, and whether on 
anticancer treatment. Included as 
data on patients with COVID-19 
who have cancer are lacking 
 Among patients with cancer and 
COVID-19, 30-day all-cause 
mortality was high and associated 
with general risk factors and risk 




Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type Author(s) 
30.05.2020 COVID-19 in Africa: no room for 
complacency 
The Lancet | Editorial   
30.05.2020 Fears of “highly catastrophic” 
COVID-19 spread in Yemen 
The Lancet | World 
Report 
Sharmila Devi 
29.05.2020 Covid-19 study on 
hydroxychloroquine use 
questioned by 120 researchers and 
medical professionals 
The Guardian | News Melissa Davey 
29.05.2020 COVID-19 research in Africa Science | Editorial Linda-Gail Bekker 
Valerie Mizrahi 
29.05.2020 Paying participants in COVID-19 
trials 
The Journal of 
Infectious Diseases | 
Review 
Emily A. Largent 
Holly Fernandez 
Lynch 
28.05.2020 The starting line for COVID-19 
vaccine development 









27.05.2020 A voice from the front line: reaching 
out of the box to engage private 
non-state healthcare actors in 
LMICs to combat COVID-19 
Health Policy and 




May 2020 First measles, now COVID-19 – are 
outbreaks finally moving the dial on 
vaccine hesitancy? 
LSHTM | Feature Jacqui Thornton 
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Online learning & events 




09:30 am to 
11:00 am 
EDT 
Virtual Event - No 
backsliding: How can 
we re-orient food 
systems and health 
systems to protect 
nutrition and healthy 
diets in the context of 
COVID-19? 




Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours per 
week 
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Development: John 
Nkengasong 
Event   CGD 
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online brief with Dr 
David Nabarro 
Event 1h 4SD 
30.04.2020 Professor Chris 
Whitty’s Gresham 
lecture on COVID-19 
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Rapid review methodology 
The rapid daily search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa”) OR (“equity” OR “equities”) OR (“poverty”), restricted to 
articles published in the previous 2 to 3 days, in English. This is complemented by a search of the homepage of 
the following high-impact global health journals: The Lancet journals, New England Journal of Medicine, Nature, 
JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ Global Health, the PLoS journals and a Twitter 
search of their Twitter pages. A search also of preprints from bioRxiv and medRxiv. Please note that papers that 
have not been peer-reviewed are highlighted in red. All primary research papers that relate to the primary and 
secondary impacts of the COVID-19 response in LMICs, and disease control and health system responses are 
included. Articles related to tackling the secondary impacts on other sectors are not included. Additional 
commentaries, opinions, and commissioned pieces are selected based on relevance. 
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
About this report 
This daily COVID-19 health evidence summary (HES) is based on 3 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Department for 
International Development (DFID) and its partners in support of pro-poor programmes. 
It is licensed for non-commercial purposes only. K4D cannot be held responsible for 
errors, omissions or any consequences arising from the use of information contained in 
this health evidence summary. Any views and opinions expressed do not necessarily 
reflect those of DFID, K4D or any other contributing organisation.  
© DFID - Crown copyright 2020. 
 
